

1. Scope

Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers and temporary staff worldwide (“Covered Persons”). Consultants, contract workers, and temporary staff are not Amgen employees, and nothing in this Policy should be construed to the contrary.

2. Policy

It is Amgen’s policy to comply with all regulations and laws worldwide relating to Adverse Event (“AE”) reporting. All Covered Persons are responsible for reporting AEs to Amgen Global Safety (or their Local Safety Unit) within one business day of learning of the AE. It is Amgen’s mission to serve patients, and prompt and accurate reporting of AEs is critical to protecting the health and safety of patients who use Amgen’s products around the world. Amgen will train all Covered Persons on the requirements of this Policy annually.

Adverse Event (or Adverse Experience)

An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.

An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. This includes:

- Any clinically significant worsening of a pre-existing condition;
- An AE occurring from medication error or overdose of a product, whether accidental or intentional;
- An AE occurring from abuse (i.e., use for non-clinical reasons) of a product;
- An AE that has been associated with the discontinuation of the use of a product; and
- Any lack or loss of intended effect.

For purposes of this Policy, exposure to Amgen products while pregnant and/or breast feeding must be reported to Amgen Global Safety. In addition, any event involving medication errors, overdose, misuse or abuse must be reported, regardless of whether associated with an AE.

It does not matter whether the AE is thought to be caused or even not caused by taking the Amgen product – all AEs must be reported to Amgen Global Safety. In addition, Covered Persons may learn of AEs during business transactions (e.g., a sales call) or non-business events (e.g., a dinner) and both must be reported per the requirements of this Policy.

This Policy does not apply to formal data collection processes such as clinical trials or observational studies with formal protocols in place to collect analyze and report AEs. This Policy does apply to Covered Persons involved in market research activities. If in doubt whether the Policy applies, Covered Persons should report the AE.

How to Report an Adverse Event

- Report information on AEs to your local Amgen safety office. Contact numbers for local safety offices are posted on the Amgen Web site. Alternatively, Covered Persons may contact corporate headquarters using the following contact numbers:

Amgen Global Safety

Phone: 8-447-3505 or +1-800-772-6436 (+1-800-77-Amgen)

Fax: +1-888-814-8653

- Your reporting obligations are met by directly calling or faxing the AE into your local safety office or Amgen Global Safety within one business day. Your obligations are not met by putting the AE in business reports, such as call notes, emails to your manager, etc.
- Covered Persons should try to obtain details that will assist Amgen in its follow-up, e.g., a patient identifier, such as date of birth or initials, a description of the AE, the Amgen product, and reporter contact details. Please note that any information collected about an individual person or persons must comply with applicable privacy and data protection laws and regulations, along with Amgen policies. If you have any questions or require direction, contact your local Amgen affiliate's data protection officer or the Amgen Privacy Office.
- Information about AEs must be kept confidential. Covered Persons should not discuss any information concerning an AE with anyone except the reporting person or entity, supervising staff, staff in Global Safety, Medical Information staff, Amgen Operations staff, and the Law Department, unless otherwise directed.

3. Additional Information

Covered Persons Responsibility for Compliance

Every Covered Person worldwide is required to follow (1) the Amgen Code of Conduct, (2) laws and regulations applicable in the relevant jurisdictions, and (3) Amgen governance documents applicable to him or her, including without limitation, those relating to this Policy. Covered Persons should exert due diligence in preventing violations of such laws, regulations, and governance documents. Covered Persons must refer to the governance documents in effect for the geographic area in which they work, or for which they are responsible, or request guidance from their manager or compliance representative with responsibility for that geographic area. See Section 4, below, for a non-exhaustive list of governance documents related to this Policy. The term "governance documents" in this Policy means Amgen's written policies, standards, procedures, business practices, and manuals.

Amgen expects its managers to (1) be familiar with (or take appropriate steps to become familiar with) the laws, regulations, and Amgen governance documents applicable to the activities they manage or supervise, (2) provide that their direct reports have appropriate training on compliance issues to perform their job functions, and (3) supervise their direct reports with respect to compliance requirements and activities.

If Amgen determines that any Covered Person has violated this Policy, related standards, procedures or controls, applicable laws or regulations, or any governance documents, appropriate disciplinary measures will be taken, up to and including immediate termination of employment, to the extent permitted by applicable laws. The following is a non-exhaustive list of possible disciplinary measures to which Covered

Persons may be subject (subject to applicable law): oral or written warning, suspension, removal of job duties/responsibilities, demotion, reduction in compensation, and/or termination of employment.

Subject to applicable laws, Amgen reserves the right to take whatever disciplinary or other measure(s) it determines in its sole discretion to be appropriate in any particular situation, including disclosure of the wrongdoing to governmental authorities. Nothing in this Policy changes the at-will nature of employment at Amgen, its affiliates or subsidiaries, where applicable. Amgen may also terminate the services or work engagement of non-employee Covered Persons for violation of this Policy.